Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma

Hypertension

Volumn 61, Issue 2, 2013, Pages 526-533

  Rossitto, Giacomo ^a   Regolisti, Giuseppe ^b   Rossi, Ermanno ^b   Negro, Aurelio ^b   Nicoli, Davide ^b   Casali, Bruno ^b   Toniato, Antonio ^a   Caroccia, Brasilina ^a   Seccia, Teresa Maria ^a   Walther, Thomas ^c   Rossi, Gian Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

angiotensin II; antibodies; AT1 receptor; autoimmunity; primary aldosteronism

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR AUTOANTIBODY; ANTIBODY; CAPTOPRIL; RENIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; MALE; PREECLAMPSIA; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL;

ADENOMA; ADRENAL CORTEX NEOPLASMS; ADULT; AGED; ALDOSTERONE; AUTOANTIBODIES; AUTOIMMUNITY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MIDDLE AGED; PRE-ECLAMPSIA; PREGNANCY; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 84873060804     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.202945     Document Type: Article

References (45)

1. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293-2300. (Pubitemid 44873058)
2. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab. 2008;19:88-90. (Pubitemid 351442920)
3. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248. (Pubitemid 40523144)
4. Omura M, Sasano H, Fujiwara T, Yamaguchi K, Nishikawa T. Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metab Clin Exp. 2002;51:350-355. (Pubitemid 34232637)
5. Gomez-Sanchez CE, Rossi GP, Fallo F, Mannelli M. Progress in primary aldosteronism: present challenges and perspectives. Horm Metab Res. 2010;42:374-381.
6. Nawata H, Takayanagi R, Ohnaka K, Sakai Y, Imasaki K, Yanase T, Ikuyama S, Tanaka S, Ohe K. Type 1 angiotensin II receptors of adrenal tumors. Steroids. 1995;60:28-34.
7. Sarzani R, Opocher G, Dessì-Fulgheri P, Paci V, Cola G, Rocco S, Vianello B, Mantero F, Rappelli A. Expression of type 1 angiotensin II receptors in human aldosteronomas. Endocr Res. 1995;21:189-195.
8. Breault L, Lehoux JG, Gallo-Payet N. Angiotensin II receptors in the human adrenal gland. Endocr Res. 1996;22:355-361. (Pubitemid 26424349)
9. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103:945-952. (Pubitemid 29169601)
10. Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, Sjögren KG, Hjalmarson A, Müller-Esterl W, Hoebeke J. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens. 2000;18:945-953. (Pubitemid 30459497)
11. Liao YH, Wei YM, Wang M, Wang ZH, Yuan HT, Cheng LX. Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res. 2002;25:641-646.
12. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352:558-569. (Pubitemid 40204669)
13. Walther T, Stepan H. Agonist autoantibodies against the angiotensin AT1 receptor in renal and hypertensive disorders. Curr Hypertens Rep. 2007;9:128-132. (Pubitemid 46779377)
14. Dechend R, Homuth V, Wallukat G, Kreuzer J, Park JK, Theuer J, Juepner A, Gulba DC, Mackman N, Haller H, Luft FC. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation. 2000;101:2382-2387. (Pubitemid 30329128)
15. Herse F, Dechend R, Harsem NK, Wallukat G, Janke J, Qadri F, Hering L, Muller DN, Luft FC, Staff AC. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension. 2007;49:604-611.
16. Walther T, Wallukat G, Jank A, Bartel S, Schultheiss HP, Faber R, Stepan H. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension. 2005;46:1275-1279. (Pubitemid 43189723)
17. Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. J Hypertens. 2008;26:613-621. (Pubitemid 351354903)
18. Rossi GP, Seccia TM, Pessina AC. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit Rev Clin Lab Sci. 2007;44:1-85. (Pubitemid 44973616)
19. Dechend R, Viedt C, Müller DN, Ugele B, Brandes RP, Wallukat G, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation. 2003;107:1632-1639. (Pubitemid 36401560)
20. Thway TM, Shlykov SG, Day MC, Sanborn BM, Gilstrap LC III, Xia Y, Kellems RE. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation. 2004;110:1612-1619. (Pubitemid 39297984)
21. Yang X, Wang F, Chang H, Zhang S, Yang L, Wang X, Cheng X, Zhang M, Ma XL, Liu H. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. J Hypertens. 2008;26:1629-1635.
22. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008;14:855-862.
23. Parrish MR, Wallace K, Tam Tam KB, Herse F, Weimer A, Wenzel K, Wallukat G, Ray LF, Arany M, Cockrell K, Martin JN, Dechend R, LaMarca B. Hypertension in response to AT1-AA: role of reactive oxygen species in pregnancy-induced hypertension. Am J Hypertens. 2011;24: 835-840.
24. Xia Y, Ramin SM, Kellems RE. Potential roles of angiotensin receptor- activating autoantibody in the pathophysiology of preeclampsia. Hypertension. 2007;50:269-275. (Pubitemid 47205769)
25. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004;109:2792-2800. (Pubitemid 38737927)
26. Yamada M, Kushibiki M, Osanai T, Tomita H, Okumura K. Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovasc Res. 2008;79: 169-178. (Pubitemid 351881932)
27. Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768-772.
28. Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension. 2012;59:592-598.
29. Maniero C, Fassina A, Seccia TM, Toniato A, Iacobone M, Plebani M, De Caro R, Calò LA, Pessina AC, Rossi GP. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens. 2012;30:390-395.
30. Pilz S, Kienreich K, Drechsler C, Ritz E, Fahrleitner-Pammer A, Gaksch M, Meinitzer A, März W, Pieber TR, Tomaschitz A. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab. 2012;97:E75-E79.
31. Rossi GP, Ragazzo F, Seccia TM, Maniero C, Barisa M, Calò LA, Frigo AC, Fassina A, Pessina AC. Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension. 2012;60:431-436.
32. Nakamura Y, Satoh F, Morimoto R, Kudo M, Takase K, Gomez-Sanchez CE, Honma S, Okuyama M, Yamashita K, Rainey WE, Sasano H, Ito S. 18-oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism. J Clin Endocrinol Metab. 2011;96:E1272-E1278.
33. Rossi GP, Seccia TM, Pessina AC. A diagnostic algorithm-the holy grail of primary aldosteronism. Nat Rev Endocrinol. 2011;7:697-699.
34. Azizan EA, Murthy M, Stowasser M, Gordon R, Kowalski B, Xu S, Brown MJ, O'Shaughnessy KM. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension. 2012;59:587-591.
35. Klemm SA, Ballantine DM, Tunny TJ, Stowasser M, Gordon RD. PCRSSCP analysis of the angiotensin II type 1 receptor gene in patients with aldosterone-producing adenomas. Clin Exp Pharmacol Physiol. 1995;22:457-459.
36. Davies E, Bonnardeaux A, Plouin PF, Corvol P, Clauser E. Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma. J Clin Endocrinol Metab. 1997;82:611-615. (Pubitemid 27068638)
37. Sachse R, Shao XJ, Rico A, Finckh U, Rolfs A, Reincke M, Hensen J. Absence of angiotensin II type 1 receptor gene mutations in human adrenal tumors. Eur J Endocrinol. 1997;137:262-266. (Pubitemid 27405110)
38. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867. (Pubitemid 36019639)
39. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today. 1993;14:426-430. (Pubitemid 23271739)
40. Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, Azizan EA, Aigbirhio F, Gurnell M, Brown MJ. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metab. 2012;97:100-109.
41. Kvakan H, Luft FC, Muller DN. Role of the immune system in hypertensive target organ damage. Trends Cardiovasc Med. 2009;19: 242-246.
42. Verlohren S, Muller DN, Luft FC, Dechend R. Immunology in hypertension, preeclampsia, and target-organ damage. Hypertension. 2009;54: 439-443.
43. Abboud FM, Harwani SC, Chapleau MW. Autonomic neural regulation of the immune system: implications for hypertension and cardiovascular disease. Hypertension. 2012;59:755-762.
44. Wenzel K, Rajakumar A, Haase H, Geusens N, Hubner N, Schulz H, et al. Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension. 2011;58: 77-84.
45. Bobst SM, Day MC, Gilstrap LC III, Xia Y, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am J Hypertens. 2005;18:330-336. (Pubitemid 40409912)